profit from every $100 of sales.
$0$100
Inotiv
We have no price for Inotiv since 27 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.01+0.00% today
-99.2% since Oct 13, 25
1-year low $0.011-year high $1.43
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Inotiv sold, what it kept, and what it did with the cash.
Sales went from $548 million in 2022 to $513 million in 2025, with -$68.6 million of profit last year.
SalesProfit
Inotiv vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Inotiv | No profit yet | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Inotiv's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 548 | 572 | 491 | 513 | |
| 157 | 182 | 111 | 121 | |
| 20 | -9 | -54 | -37 | |
| -273 | -27 | -27 | 25 | |
| -337 | -105 | -108 | -69 | |
| -13.84 | -4.10 | -4.19 | -2.11 | |
| 28.7% | 31.8% | 22.7% | 23.6% | |
| 3.7% | -1.6% | -11.1% | -7.2% | |
| -61.5% | -18.4% | -22.1% | -13.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 963 | 857 | 781 | 771 |
| Cash | 19 | 35 | 21 | 22 |
| Total debt | 386 | 418 | 446 | 459 |
| Total liabilities | 603 | 588 | 611 | 635 |
| 360 | 269 | 171 | 136 | |
| 24 | 26 | 26 | 32 | |
| -34.1% | -9.3% | -10.8% | -4.1% | |
| -93.5% | -39.1% | -63.6% | -50.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -5 | 28 | -7 | -10 | |
| 36 | 28 | 22 | 17 | |
| -42 | 0 | -29 | -27 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 24 | 8 | 7 | 6 |
Valuation
- –
- –
- –
- 0.1×
- 0.0×
- –
- 17.8×
- -971.1%
- -2,461.8%
- 0.0%
Profitability
- 23.6%
- -7.2%
- -13.4%
- 4.8%
- -4.1%
- -17.0%
- -50.8%
- -9.4%
- -16.2%
- –
Growth
- −2.2%
- –
- +7.0%
- –
- +25.2%
Financial health
- 21.0×
- 4.85
- 72.0%
- -0.6×
- 0.30
- 0.22
- 0.70
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 25%of 964
Bottom 14%of 898
Bottom 12%of 911
What analysts expect
- Average price target
- $3.00
- Range
- $3.00 – $3.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.94 | -0.64 | −48.0% |
| Feb 9, 2026 | -0.72 | -0.64 | −12.9% |
| Dec 3, 2025 | -0.14 | -0.08 | −75.0% |
| Aug 6, 2025 | -0.12 | -0.15 | +20.0% |
| May 7, 2025 | -0.18 | -0.24 | +25.0% |
| Feb 5, 2025 | -0.42 | -0.42 | +0.0% |
| Dec 3, 2024 | -0.16 | -0.91 | +82.4% |
| Aug 8, 2024 | -0.20 | -0.09 | −122.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
15No pass
Benjamin Graham
36No pass
Philip Fisher
17No pass
Peter Lynch
0No pass
Joel Greenblatt
0No pass
Charlie Munger
7No pass
Terry Smith
5No pass
Questions about Inotiv
Is Inotiv a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Inotiv AI analysis
What does Inotiv do?
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It is in Medical - Diagnostics & Research.
Does Inotiv pay a dividend?
No. Inotiv does not pay a dividend at the moment.
Is Inotiv stock halal?
No. Inotiv does not pass our halal screen: its debt is 16,476% of its market value, at or above the 33% limit. How we check
Who are Inotiv's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Inotiv's.
Prices: daily closes to Jul 27, 2026. Fundamentals: company reports via invest-like data.